ATP-Sensitive Potassium Channels in Migraine: Translational Findings and Therapeutic Potential
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
ATP-Sensitive Potassium Channels in Migraine : Translational Findings and Therapeutic Potential. / Clement, Amalie; Guo, Song; Jansen-Olesen, Inger; Christensen, Sarah Louise.
I: Cells, Bind 11, Nr. 15, 2406, 2022.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - ATP-Sensitive Potassium Channels in Migraine
T2 - Translational Findings and Therapeutic Potential
AU - Clement, Amalie
AU - Guo, Song
AU - Jansen-Olesen, Inger
AU - Christensen, Sarah Louise
PY - 2022
Y1 - 2022
N2 - Globally, migraine is a leading cause of disability with a huge impact on both the work and private life of affected persons. To overcome the societal migraine burden, better treatment options are needed. Increasing evidence suggests that ATP-sensitive potassium (K-ATP) channels are involved in migraine pathophysiology. These channels are essential both in blood glucose regulation and cardiovascular homeostasis. Experimental infusion of the K-ATP channel opener levcromakalim to healthy volunteers and migraine patients induced headache and migraine attacks in 82-100% of participants. Thus, this is the most potent trigger of headache and migraine identified to date. Levcromakalim likely induces migraine via dilation of cranial arteries. However, other neuronal mechanisms are also proposed. Here, basic K-ATP channel distribution, physiology, and pharmacology are reviewed followed by thorough review of clinical and preclinical research on K-ATP channel involvement in migraine. K-ATP channel opening and blocking have been studied in a range of preclinical migraine models and, within recent years, strong evidence on the importance of their opening in migraine has been provided from human studies. Despite major advances, translational difficulties exist regarding the possible anti-migraine efficacy of K-ATP channel blockage. These are due to significant species differences in the potency and specificity of pharmacological tools targeting the various K-ATP channel subtypes.
AB - Globally, migraine is a leading cause of disability with a huge impact on both the work and private life of affected persons. To overcome the societal migraine burden, better treatment options are needed. Increasing evidence suggests that ATP-sensitive potassium (K-ATP) channels are involved in migraine pathophysiology. These channels are essential both in blood glucose regulation and cardiovascular homeostasis. Experimental infusion of the K-ATP channel opener levcromakalim to healthy volunteers and migraine patients induced headache and migraine attacks in 82-100% of participants. Thus, this is the most potent trigger of headache and migraine identified to date. Levcromakalim likely induces migraine via dilation of cranial arteries. However, other neuronal mechanisms are also proposed. Here, basic K-ATP channel distribution, physiology, and pharmacology are reviewed followed by thorough review of clinical and preclinical research on K-ATP channel involvement in migraine. K-ATP channel opening and blocking have been studied in a range of preclinical migraine models and, within recent years, strong evidence on the importance of their opening in migraine has been provided from human studies. Despite major advances, translational difficulties exist regarding the possible anti-migraine efficacy of K-ATP channel blockage. These are due to significant species differences in the potency and specificity of pharmacological tools targeting the various K-ATP channel subtypes.
KW - K-ATP channels
KW - provoked migraine
KW - SUR
KW - Kir6
KW - x
KW - levcromakalim
KW - glibenclamide
KW - human migraine model
KW - in vivo models
KW - migraine
KW - PANCREATIC BETA-CELLS
KW - GENE-RELATED PEPTIDE
KW - K-ATP
KW - NITRIC-OXIDE
KW - INSULIN-SECRETION
KW - SULFONYLUREA RECEPTOR
KW - NEUROPATHIC PAIN
KW - IN-VITRO
KW - ACTIVATION
KW - HYPERPOLARIZATION
U2 - 10.3390/cells11152406
DO - 10.3390/cells11152406
M3 - Review
C2 - 35954249
VL - 11
JO - Cells
JF - Cells
SN - 2073-4409
IS - 15
M1 - 2406
ER -
ID: 317434411